Clinical Trial Imaging Market: Growth, Size, Share, and Trends

Report Code MD 4818
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029

Overview

The global clinical trial imaging market is projected to reach USD 2.07 billion by 2029 from USD 1.42 billion in 2024, at a CAGR of 7.8%. Increasing funding in research and development aimed at producing novel disease-fighting medications, coupled with the expansion of biotechnology and pharmaceutical firms, and increasing number of CROs, is expected to drive the market growth. However on the other hand, imaging equipments being slightly overpriced was responsible for growth of imaging services market as well as hindering the growth of the market.

Attractive Opportunities in the Clinical Trial Imaging Market

Asia Pacific

The Asia Pacific market is expected to witness high growth during the forecast period owing to the high growth potential showcased by emerging countries such as India and China.

The increase in R&D spending, growth in the pharmaceutical and biotechnology industry and the increasing number of CROs are driving the clinical trial imaging market.

The surge in healthcare expenditure is expected to create a greater opportunity for the market.

Emerging markets are expected to offer lucrative growth opportunities for players in this market.

Product launches and acquisitions were the most widely adopted growth strategies by market players.

Global Clinical Trial Imaging Market Dynamics

Driver: Rise in research and development expenditures

Pharmaceutical and biotechnology companies are well-known for their major spending in research and development with a motive of developing novel drug molecules. This factor is likely to impact and benefit the clinical trial imaging market as research is the base for clinical trials followed by growth in developing services useful in the life science sector for diagnosis as well for medical use.

Restraint: Significant expenses associated with the adoption of imaging systems

One of the main focuses in the healthcare industry is finding ways to reduce the rising costs of healthcare services. To achieve this goal, a wide spectrum of industry participants are actively g and developing a variety of approaches. But the basic question of which service and equipment to spend upon is turning out to be a bigger problem. As the prices of these imaging devices and their charges for purchase, installation need to be in accordance with the services that are provided. This initial financial burden, coupled with ongoing maintenance outlays, exerts a dampening influence on market expansion. Additionally, to effectively utilize such equipment, imaging service providers necessitate the engagement of skilled professionals, including experienced radiologists. These combined factors contribute to the substantial implementation costs associated with imaging systems, thereby acting as a significant deterrent to the growth trajectory of the clinical trial imaging market

 

Opportunity: Growth opportunities in emerging economies

Emerging nations like India, South Korea, Brazil, and Mexico present substantial growth prospects for participants in the clinical trial imaging sector. Global market is interested in investing in theses countries for research and development as these countries serve good purpose for turning the research market into a commercial plan. Also, with increase in global clinical trial imaging market, imaging services and other services are meant to grow huge in coming years.

Moreover, in the Asian countries predominantly India and China, these countries encourage and have presence of a lot of Contract Research Organizations (CROs) which are continuously on the loop to the Asian markets, particularly China and India, are home to numerous Contract Research Organizations (CROs) that ready to make provision for drug discovery services to pharmaceutical and biotechnology companies. Currently wityh such huge interest and substantial growth in research and development funding and the presence of CROs in developing economies, there seems to be extraordinary rise in need of clinical trial imaging in the forthcoming years.

Challenge: Elevated expenses associated with conducting clinical trials

Research endeavors pertaining to healthcare progress invariably encompass clinical trials. These trials constitute a fundamental component for substantiating the efficacy of innovations, encompassing therapeutics, pharmaceuticals, medical apparatus, diagnostics, and scholarly investigations. While laboratory experiments strive to replicate human physiological conditions, the validation of a drug's effectiveness and safety within the targeted population necessitates a critical phase – conducting clinical trials. Nonetheless, orchestrating such trials to meticulously document the impact of therapies or drugs and vigilantly monitor potential adverse effects constitutes a financially demanding undertaking.

Global Clinical Trial Imaging Market Ecosystem Analysis

 

In 2023, services segment accounted for the largest share of the clinical trial imaging market, by services and software

Based on product and services, the clinical trial imaging market is divided into services and software segments. To note down, in 2023, the services segment sprung up as the leading contributor to the clinical trial imaging market, basically as services included consulting services for clinical study design, management, and implementation of medical image data; operational services for different imaging modalities; system and technical support services; image processing and read analysis services; and clinical imaging data management services. Also, growing investments in R&D rose followed by gradual increase in the global pharmaceutical and biotechnology industries which further fueled the services market.

In 2023, computed tomography segment held the largest share of the clinical trial imaging market, by modality

The clinical trial imaging market when segregated on terms of modality have computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities based on modality. Notably, in 2023, the computed tomography segment captured the predominant portion of the market share. This prominence can be attributed to factors including the rising presence of Contract Research Organizations (CROs), amplified research and development investments, and the expansion of the pharmaceutical and biotechnology sectors, collectively propelling this market segment.

In 2023, pharmaceutical companies maintained the top position for having the largest share in the clinical trial imaging market, by end users

The clinical trial imaging market has been segregated into pharmaceutical & biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes and other end users based on end users. The industry for clinical trial imaging was highly dominated in 2023 by the pharmaceutical & biotechnology companies segment. As this industry is refining quickly, there is a always a growing demand for new drugs and therapies used for chronic illnesses. Thus creating more pressure for pharmaceutical & biotech companies to be able to supply novel drugs and therapies in the market continuously to maintain their dominance. The market is expected to grow at a faster and compound rate due to the interrelationship between the impressive range of novel medications that pharmaceutical & biotech companies have umasked and the increase in demand for clinical trial imaging.

North America is the largest regional market for clinical trial imaging market

The global clinical trial imaging market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America accounted for the largest share of the global clinical trial imaging market. The North American clinical trial imaging market's growth can be attributed to the, to the presence of big outsourcing companies and an increase in R&D in the region. Various factors such as the increasing geriatric population along with growing chronic diseases are projected to drive the market in North America. North America also performs the maximum number of clinical trials.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of Clinical Trial Imaging Market

  • In March 2023, ICON Plc. (Ireland) brodcasted that the company has signed a partnership with LEO Pharma (Denmark) to upmarket the clinical trials which can be patient-centric and cost effective, and which will uplift the company’s overall passion of building one of the most novel and efficient clinical portfolio execution organisations in the industry.
  • In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials.

Key Market Players

KEY PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Clinical Trial Imaging Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Billion)
Segments covered Service & software, modality, therapeutic area, end user and region
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC

 

Key Questions Addressed by the Report

What are the restraints most likely impacting the clinical trial imaging market?
The consequent costing interlinked with equipment attainment and installation, as well as the considerable costs required to conducting clinical trials, have the potential to restrain market growth throughout the projected periods.
What are the major product and services of clinical trial imaging market?
The clinical trial imaging market is subdivided into services and software based on services and software. In 2023, the services segment held the position for acquiring major share. Presence of prominent pharmaceutical and biotechnology industries and their growing R&D along with increasing number of CROs carrying out clinical trials are major drivers for the growth of the services market.
Who are the key players in the clinical trial imaging market?
The key players in this market are ICON plc. (Ireland), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), Anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Who are the major end users of clinical trial imaging market?
Based on end users, the clinical trial imaging market has been segmented into pharmaceutical & biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes and other end users based. In 2023, the p harmaceutical & biotechnology segment accounted for the largest share of the clinical trial imaging market. The burgeoning pharmaceutical sectors, coupled with heightened investments in research and development for the creation of novel disease-treating drugs, are anticipated to propel market expansion.
Which region is lucrative for the clinical trial imaging market?
Much like China, India, and Japan, the burgeoning economies within the Asia Pacific region are poised to emerge as highly profitable markets for the clinical trial imaging sector.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Clinical Trial Imaging Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
30
RESEARCH METHODOLOGY
34
EXECUTIVE SUMMARY
45
PREMIUM INSIGHTS
49
MARKET OVERVIEW
52
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing R&D spending in pharmaceutical and biotechnology companies
    - Rising number of clinical trials in medical research
    - Growth in pharmaceutical and biotechnology industries
    - Increasing number of contract research organizations
    RESTRAINTS
    - High implementation cost of imaging systems
    OPPORTUNITIES
    - Growth opportunities in emerging economies
    - Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    CHALLENGES
    - High cost of clinical trials
  • 5.3 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
  • 5.4 PATENT ANALYSIS
    LIST OF MAJOR PATENTS, 2022–2023
  • 5.5 TRADE ANALYSIS
    TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
    - Import data for X-ray apparatus
    - Export data for X-ray apparatus
    TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
    - Import data for CT apparatus
    - Export data for CT apparatus
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    ROLE IN ECOSYSTEM
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
  • 5.13 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - CT and MRI
    COMPLEMENTARY TECHNOLOGIES
    - Ultrasound
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 CASE STUDY ANALYSIS
    REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
  • 5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET
CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE
76
  • 6.1 INTRODUCTION
  • 6.2 SERVICES
    OPERATIONAL IMAGING SERVICES
    - Rising number of CROs and growing pharmaceutical industry to drive market
    READ ANALYSIS SERVICES
    - Increasing number of clinical trials and rising R&D spending to support market growth
    SYSTEM AND TECHNICAL SUPPORT SERVICES
    - Need for continuous technical support to propel segment growth
    TRIAL DESIGN AND CONSULTING SERVICES
    - High R&D spending and favorable government initiatives for clinical trials to fuel market growth
  • 6.3 SOFTWARE
    NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH
CLINICAL TRIAL IMAGING MARKET, BY MODALITY
90
  • 7.1 INTRODUCTION
  • 7.2 COMPUTED TOMOGRAPHY
    HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
  • 7.3 MAGNETIC RESONANCE IMAGING
    GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
  • 7.4 ULTRASOUND
    COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
  • 7.5 POSITRON EMISSION TOMOGRAPHY
    ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
  • 7.6 X-RAY
    LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
  • 7.7 OTHER MODALITIES
CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA
106
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
  • 8.3 INFECTIOUS DISEASES
    RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
  • 8.4 NEUROLOGY
    HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
  • 8.5 CARDIOVASCULAR SYSTEM DISORDERS
    HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
  • 8.6 ENDOCRINOLOGY
    RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
  • 8.7 IMMUNOLOGICAL DISORDERS
    WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
  • 8.8 OTHER THERAPEUTIC AREAS
CLINICAL TRIAL IMAGING MARKET, BY END USER
124
  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
  • 9.3 MEDICAL DEVICE MANUFACTURERS
    HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
    INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
  • 9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
    RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
  • 9.6 OTHER END USERS
CLINICAL TRIAL IMAGING MARKET, BY REGION
139
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American clinical trial imaging market during study period
    CANADA
    - Increase in per capita healthcare spending to augment market growth
  • 10.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
    UK
    - Increased R&D investments and high per capita healthcare expenditure to augment market growth
    FRANCE
    - Developed generics market and favorable government healthcare policies to support market growth
    ITALY
    - Increasing number of drug approvals and rising investments in clinical trials to drive market
    SPAIN
    - Increased biologics production and improved healthcare infrastructure to aid market growth
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Favorable government regulations and presence of large target patient population to boost market growth
    JAPAN
    - Increasing geriatric population and rising healthcare expenditure to favor market growth
    INDIA
    - Increased government focus on developing advanced healthcare infrastructure to augment market growth
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increasing investments in biopharmaceutical research to propel market growth
    MEXICO
    - Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
    REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
198
  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
  • 11.3 REVENUE ANALYSIS, 2021–2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Service & software footprint
    - Therapeutic area footprint
    - Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.8 COMPETITIVE SCENARIO
    SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
    DEALS
COMPANY PROFILES
210
  • 12.1 KEY PLAYERS
    ICON PLC
    - Business overview
    - Services/Solutions offered
    - Recent developments
    - MnM view
    MEDPACE
    - Business overview
    - Services/Solutions offered
    - MnM view
    CLARIO
    - Business overview
    - Services/Solutions offered
    - Recent developments
    - MnM view
    IXICO PLC
    - Business overview
    - Services/Solutions offered
    - Recent developments
    RESONANCE HEALTH LTD.
    - Business overview
    - Services/Solutions offered
    - Recent developments
    RADIANT SAGE
    - Business overview
    - Services/Solutions offered
    WCG CLINICAL
    - Business overview
    - Services/Solutions offered
    - Recent developments
    CARDIOVASCULAR IMAGING TECHNOLOGIES
    - Business overview
    - Services/Solutions offered
  • 12.2 OTHER PLAYERS
    MEDICAL METRICS, INC.
    PRISM CLINICAL IMAGING
    BOSTON IMAGING CORE LAB
    ANAGRAM 4 CLINICAL TRIALS
    VOIANT
    CALYX
    BIOSPECTIVE INC.
    PROSCAN IMAGING
    MICRON, INC.
    IMAGING ENDPOINTS
    PERSPECTUM
    PHARMTRACE
    NAVITAS LIFE SCIENCES
    MEDIAN TECHNOLOGIES
    INVICRO, LLC
    IMAGE CORE LAB
    IMAGE ANALYSIS GROUP (IAG)
APPENDIX
241
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
  • TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS, JANUARY 2022–DECEMBER 2023
  • TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM
  • TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTER’S FIVE FORCES
  • TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS
  • TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023–DECEMBER 2024
  • TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 152 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 2020–2023
  • TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 170 EUROPE: KEY MACROINDICATORS
  • TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029(USD MILLION)
  • TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 234 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
  • TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
  • TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION
  • TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT
  • TABLE 264 CLINICAL TRIAL IMAGING MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 265 CLINICAL TRIAL IMAGING MARKET: REGION FOOTPRINT
  • TABLE 266 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 267 CLINICAL TRIAL IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
  • TABLE 268 CLINICAL TRIAL IMAGING MARKET: SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
  • TABLE 269 CLINICAL TRIAL IMAGING MARKET: DEALS, JANUARY 2020–AUGUST 2024
  • TABLE 270 ICON PLC: COMPANY OVERVIEW
  • TABLE 271 ICON PLC: SERVICES/SOLUTIONS OFFERED
  • TABLE 272 ICON PLC: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
  • TABLE 273 ICON PLC: DEALS, JANUARY 2020–AUGUST 2024
  • TABLE 274 MEDPACE: COMPANY OVERVIEW
  • TABLE 275 MEDPACE: SERVICES/SOLUTIONS OFFERED
  • TABLE 276 CLARIO: COMPANY OVERVIEW
  • TABLE 277 CLARIO: SERVICES/SOLUTIONS OFFERED
  • TABLE 278 CLARIO: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
  • TABLE 279 CLARIO: DEALS, JANUARY 2020–AUGUST 2024
  • TABLE 280 IXICO PLC: COMPANY OVERVIEW
  • TABLE 281 IXICO PLC: SERVICES/SOLUTIONS OFFERED
  • TABLE 282 IXICO PLC: DEALS, JANUARY 2020–AUGUST 2024
  • TABLE 283 IXICO PLC: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2024
  • TABLE 284 RESONANCE HEALTH LTD.: COMPANY OVERVIEW
  • TABLE 285 RESONANCE HEALTH LTD.: SERVICES/SOLUTIONS OFFERED
  • TABLE 286 RESONANCE HEALTH LTD.: SERVICE LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
  • TABLE 287 RESONANCE HEALTH LTD.: DEALS, JANUARY 2020–AUGUST 2024
  • TABLE 288 RADIANT SAGE: COMPANY OVERVIEW
  • TABLE 289 RADIANT SAGE: SERVICES/SOLUTIONS OFFERED
  • TABLE 290 WCG CLINICAL: COMPANY OVERVIEW
  • TABLE 291 WCG CLINICAL: SERVICES/SOLUTIONS OFFERED
  • TABLE 292 WCG CLINICAL: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 293 CARDIOVASCULAR IMAGING TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 294 CARDIOVASCULAR IMAGING TECHNOLOGIES: SERVICES/SOLUTIONS OFFERED
  • TABLE 295 MEDICAL METRICS, INC.: COMPANY OVERVIEW
  • TABLE 296 PRISM CLINICAL IMAGING: COMPANY OVERVIEW
  • TABLE 297 BOSTON IMAGING CORE LAB: COMPANY OVERVIEW
  • TABLE 298 ANAGRAM 4 CLINICAL TRIALS: COMPANY OVERVIEW
  • TABLE 299 VOIANT: COMPANY OVERVIEW
  • TABLE 300 CALYX: COMPANY OVERVIEW
  • TABLE 301 BIOSPECTIVE INC.: COMPANY OVERVIEW
  • TABLE 302 PROSCAN IMAGING: COMPANY OVERVIEW
  • TABLE 303 MICRON, INC.: COMPANY OVERVIEW
  • TABLE 304 IMAGING ENDPOINTS: COMPANY OVERVIEW
  • TABLE 305 PERSPECTUM: COMPANY OVERVIEW
  • TABLE 306 PHARMTRACE: COMPANY OVERVIEW
  • TABLE 307 NAVITAS LIFE SCIENCES: COMPANY OVERVIEW
  • TABLE 308 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 309 INVICRO, LLC: COMPANY OVERVIEW
  • TABLE 310 IMAGE CORE LAB: COMPANY OVERVIEW
  • TABLE 311 IMAGE ANALYSIS GROUP (IAG): COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 CLINICAL TRIAL IMAGING MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 CLINICAL TRIAL IMAGING MARKET: YEARS CONSIDERED
  • FIGURE 3 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN
  • FIGURE 4 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 CLINICAL TRIAL IMAGING MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 6 CLINICAL TRIAL IMAGING MARKET: KEY INSIGHTS FROM PRIMARIES
  • FIGURE 7 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 11 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 CLINICAL TRIAL IMAGING MARKET: STUDY ASSUMPTIONS
  • FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH
  • FIGURE 20 SERVICES TO DOMINATE CLINICAL TRIAL IMAGING SERVICE & SOFTWARE MARKET IN 2029
  • FIGURE 21 COMPUTED TOMOGRAPHY TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 ONCOLOGY TO COMMAND LARGEST MARKET SHARE IN 2029
  • FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE END-USER MARKET FROM 2024 TO 2029
  • FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 25 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2022)
  • FIGURE 27 PATENT APPLICATIONS FOR CLINICAL TRIAL IMAGING (JANUARY 2013–DECEMBER 2023)
  • FIGURE 28 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 30 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL IMAGING SERVICES/SOLUTIONS
  • FIGURE 33 KEY BUYING CRITERIA FOR MAJOR END USERS
  • FIGURE 34 CLINICAL TRIAL IMAGING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 35 R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION)
  • FIGURE 36 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2021–2023)
  • FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2023)
  • FIGURE 40 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 41 CLINICAL TRIAL IMAGING MARKET: COMPANY FOOTPRINT
  • FIGURE 42 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 ICON PLC: COMPANY SNAPSHOT
  • FIGURE 46 MEDPACE: COMPANY SNAPSHOT
  • FIGURE 47 IXICO PLC: COMPANY SNAPSHOT
  • FIGURE 48 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the clinical trial imaging market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

The four steps involved in estimating the market size are:

Secondary Research

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical trial imaging market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

The primary research data was conducted after acquiring knowledge about the clinical trial imaging market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals & ICUs, diagnostic laboratories, research institutes, research laboratories and point-of-care settings) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Note 1: *Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various clinical trial imaging products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value clinical trial imaging market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of clinical trial imaging market at the regional and country-level  
  • Relative adoption pattern of each clinical trial imaging market among key application segments at the regional and/or country-level 
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level. 
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level 

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the clinical trial imaging industry.

Market Definition

Clinical trial Imaging is used to create images during clinical trials while conducting research. Such imaging testing is mainly done using X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and positron emission tomography (PET). In clinical trials, imaging is used primarily to evaluate efficacy, endpoints, and more frequently, for safety evaluations and eligibility criteria.

Stakeholders

  • Medical Device Industries
  • Academic and Government Research Institutes
  • Diagnostic Centers
  • Market Research & Consulting Firms
  • Clinical Trial Imaging Manufacturers, Vendors, and Distributors
  • Pharmaceutical and Biotechnology Companies and Contract Research Organizations (CROs)

Report Objectives

  • To define, describe, segment, and forecast the clinical trial imaging market by service & software, modality, therapeutic area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as acquisitions, agreements, partnerships, contracts, approvals, product launches, and mergers in the clinical trial imaging market
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Previous Versions of this Report

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2029

Report Code MD 4818
Published in Oct, 2024, By MarketsandMarkets™

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2028

Report Code MD 4818
Published in Aug, 2023, By MarketsandMarkets™

Clinical Trial Imaging Market by Software & Services(Operational Imaging, Read Analysis), Modality(CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic Areas(Infectious, Oncology, CNS, CVS), End user(Pharma, biotechnology, CRO) - Global Forecast to 2026

Report Code MD 4818
Published in Jul, 2021, By MarketsandMarkets™

Clinical Trial Imaging Market by Product & Services (Software), Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-Ray), End User (Pharmaceutical Companies, Biotechnology Companies, CROs, Medical Device Manufacturers) - Global Forecast to 2021

Report Code MD 4818
Published in Dec, 2016, By MarketsandMarkets™

Clinical Trial Imaging Market by Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-rays), End User (Pharmaceutical Companies, CROs Medical device Manufacturers), Product (Services, software), and Region - Global Forecast to 2020

Report Code HIT 3751
Published in Sep, 2015, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Clinical Trial Imaging Market

User

Mar, 2021

Decode Al development designed nano human anology of all engineering military weaponry development.

DMCA.com Protection Status